신생혈관성 나이관련황반변성에서 베바시주맙 주입과 광역학요법을 병합한 일차치료 효과

유영주,박혜진,이태곤,이동원,조성원,이재흥,Young Ju Lew,Hae Jin Park,Tae Gon Lee,Dong Won Lee,Sung Won Cho,Jae Heung Lee 대한안과학회 2010 대한안과학회지 Vol.51 No.1

Purpose: To investigate the efficacy of the combined treatment of photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in patients with neovascular age-related macular degeneration. Methods: Forty-five eyes received a single session of PDT following three intravitreal bevacizumab (1.25 mg) injections at six-week intervals (IVB+PDT group). Twenty-seven eyes received three intravitreal bevacizuamb (1.25 mg) injections only at six-week intervals (IVB group). Results: After the six months of follow up, the mean BCVA (LogMAR) changed significantly from 0.62±0.34 to 0.56±0.33 in the IVB group (p=0.03) and from 0.61±0.33 to 0.48±0.21 in the IVB+PDT group (p=0.001). The mean BCVA was more improved in the IVB+PDT group (p=0.049). The mean CMT changes were significant in both groups immediately after treatment, but there was no significant difference at six months between the two groups. Ten eyes (37.0%) in the IVB group and 12 eyes (26.7%) in the IVB+PDT group required retreatments during the six months of follow-up (p=0.02). Conclusions: Significant improvement in visual acuity and reduction in central macular thickness over a six-months period were observed in both groups. The mean visual acuity was significantly better and the rate of reinjections after the initial treatment schedule was lower in the IVB+PDT group. J Korean Ophthalmol Soc 2010;51(1):35-41

삼출성 나이관련황반변성 반대안의 새로운 신생혈관 발생 빈도

이정진,유영주,조성원,김종우,Jung Jin Lee,MD,Young Ju Lew,MD,Sung Won Cho,MD,Jong Woo Kim,MD 대한안과학회 2013 대한안과학회지 Vol.54 No.10

Purpose: To investigate the development of new choroidal neovascularization in fellow eyes of patients treated for unilateral exudative age-related macular degeneration (AMD). Methods: Three hundred fourteen patients who were first diagnosed with unilateral exudative AMD and treated with intravitreal bevacizumab or ranibizumab were studied retrospectively. Results: New exudative AMD developed in 7.0% of fellow eyes after 1 year, 10.8% after 2 years and 13.7% after more than 2 years. According to the subtype of exudative AMD, there were no significant differences between classic CNV, occult or minimally classic CNV, and PCV in the incidence of new exudative AMD. After 2 years, a higher conversion rate was found in the bevacizumab-treated group than the ranibizumab-treated group. Conclusions: The cumulative incidence of involvement in fellow eyes with exudative AMD was 13.7% over 2 years.

백내장 수술 후 생긴 낭포황반부종에서의 유리체강내 트리암시놀론 주입술 일차치료 효과

김주연,김정목,유영주,김철구,조성원,이태곤.Joo Yeon Kim. MD. Joung Mok Kim. MD. Young Ju Lew. MD. PhD. Chul Gu Kim. MD. Sung Won Cho. MD. PhD. Tae Gon Lee. MD 대한안과학회 2012 대한안과학회지 Vol.53 No.3

Purpose: To report the clinical manifestations of intravitreal triamcinolone injection as a primary treatment method for patients with cystoid macular edema after cataract surgery. Methods: The present retrospective study was comprised of patients diagnosed with cystoid macular edema after cataract surgery performed between March 2006 and March 2008. To treat the edema, intravitreal triamcinolone injection was administered. Best corrected visual acuity (BCVA) and central macular thickness were measured, and complications as well as efficacy of the treatment were evaluated. Results: Twelve eyes were selected for the present study with a mean patient age of 67.3 years. The average period between cataract surgery and diagnosis of cystoid macular edema was 7.6 weeks. All 12 eyes received an intravitreal triamcinolone injection, and the patients were followed up for an average of 6.7 months. BCVA (log MAR) was changed from 0.29 ± 0.12 to 0.11 ± 0.09, showing statistically significant improvement (p = 0.000). The OCT showed that the average CMT was statistically decreased from 390.58 ± 94.98 μm to 165.17 ± 39.95 μm (p = 0.001). No complications were reported after the procedure, and vision and edema improved after one month in all 12 eyes. Conclusions: After performing intravitreal triamcinolone injection as a primary treatment method for cystoid macular edema which developed after cataract surgery, rapid recovery and improvement of vision and macular thickness were confirmed in all 12 eyes. J Korean Ophthalmol Soc 2012;53(3):428-433

베스트병으로 진단된 국내 환자의 특성과 임상경과

이지현(Ji Hyun Lee),유영주(Young Ju Lew),김재휘(Jae Hui Kim),김종우(Jong Woo Kim),김철구(Chul Gu Kim),이동원(Dong Won Lee) 대한안과학회 2021 대한안과학회지 Vol.62 No.3

목적: 베스트병으로 진단된 국내 환자들의 특징과 임상경과를 분석하고자 한다. 대상과 방법: 베스트병을 진단 받은 후 12개월 이상 추적 관찰한 환자를 대상으로 의무기록을 분석하였다. 진단 당시 질병의 단계 및 최대교정시력을 확인하였으며, 추적 관찰 기간 동안 질병의 단계 진행 여부를 확인하였다. 진단 시 및 최종 추적 관찰 시의 최대교정시력을 서로 비교하였으며, 단계의 진행이 있었던 안과 없었던 안 사이에 시력 변화 정도를 추가로 비교하였다. 결과: 전체 16명(32안)을 대상으로 연구를 시행하였으며, 평균 추적 관찰 기간은 52.1 ± 31.8개월이었다. 진단 시 베스트병 단계는 1단계 3안, 2단계 9안, 3단계 7안, 4단계 11안, 5단계 2안이었다. 추적 관찰 기간 동안 9안(28.1%)에서 단계의 진행이 관찰되었다. Logarithm of minimal angle of resolution (logMAR) 시력은 진단 시 평균 0.19 ± 0.19였으며, 최종 추적 관찰 시 평균 0.30 ± 0.27로 유의하게 악화되었다(p=0.004). 6안(18.8%)에서 logMAR 0.2 이상의 시력저하가 나타났다. 시력 악화 정도는 단계의 진행이 있었던 9안(0.25 ± 0.26)에서 단계 진행이 없었던 23안(0.05 ± 0.08)에 비해 더 큰 폭으로 나타났다(p=0.001). 결론: 베스트병 환자의 진단 시 시력은 비교적 좋은 편이었으나 시간의 경과에 따라 일부 환자에서 질병의 단계 진행과 시력저하가 나타났다. 단계의 진행은 나쁜 시력예후와 연관된 것으로 나타났다. Purpose: To evaluate the clinical characteristics and courses of Best disease in Korean patients. Methods: We retrospectively reviewed the medical records of patients with Best disease followed-up for more than 12 months after diagnosis. The disease stage and best-corrected visual acuity (BCVA) at diagnosis, and stage progression during follow-up, were evaluated. The BCVA at diagnosis was compared to that at the final follow-up. The BCVA changes were compared between those evidencing stage progression and not. Results: A total of 16 patients (32 eyes) were enrolled. The mean follow-up period was 52.1 ± 31.8 months. At diagnosis, three eyes had stage 1, nine stage 2, seven stage 3, 11 stage 4, and two stage 5 disease. During follow-up, stage progression was observed in nine eyes (28.1%). The mean logarithm of the minimal angle of resolution (logMAR) BCVA significantly worsened from 0.19 ± 0.19 at baseline to 0.30 ± 0.27 at the final follow-up (p = 0.004). In six eyes (18.8%), a deterioration of logMAR 0.2 or greater was noted. The extent of deterioration was greater in the nine eyes (0.25 ± 0.26) exhibiting stage progression than in the 24 eyes (0.05 ± 0.08) lacking such progression (p = 0.001). Conclusions: The visual acuity of Best disease patients was relatively good at diagnosis. However, stage progression and visual deterioration were noted in some patients. Stage progression was associated with a poor visual prognosis.

굴절부등 약시 환아의 치료결과에 영향을 미치는 요인

노승수,양홍석,장윤희,유영주,이종복,Seung Soo Rho,Hong Seok Yang,Yoon Hee Chang,Young Ju Lew,Jong Bok Lee 대한안과학회 2007 대한안과학회지 Vol.48 No.4

Purpose: To evaluate the factors affecting treatment outcome of children with anisometropic amblyopia. Methods: We retrospectively investigated the treatment outcome of 57 children who were diagnosed as anisometropic amblyopia. The age at initial treatment, initial best corrected visual acuity of the amblyopic eye, amount and type of anisometropia, strabismus and compliance of treatment were investigated. Results: The mean age and standard deviation at initial treatment was 5.3±1.8(3-9) years. The absolute average values of spherical and cylindrical anisometropia were 2.87±1.99D and 1.87±2.24D respectively. While compliance was significantly related to treatment outcome, the age at initial treatment, visual acuity on amblyopic eye, amount and type of anisometropia, and strabismus had no significant influence on treatment outcome. Conclusions: Treatment compliance was the most significant factor in the treatment of anisometropic amblyopia.

분지망막정맥폐쇄에 동반된 황반부종 환자에서 덱사메타손 유리체강내 삽입물의 단기임상결과

강선아,김종우,김철구,이태곤,유영주,김재휘,Sun Ah Kang,Jong Woo Kim,Chul Gu Kim,Tae Gon Lee,Young Ju Lew,Jae Hui Kim 대한안과학회 2015 대한안과학회지 Vol.56 No.1

Purpose: To evaluate short-term outcomes of intavitreal dexamethasone implant in macular edema secondary to branch retinal vein occlusion (BRVO). Methods: A retrospective review of medical records was performed for 24 patients (24 eyes) who were diagnosed with macular edema secondary to BRVO. The best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were measured before the injection and at 1 and 3 months after the injection. The values measured before and after the treatment were compared. In addition, the association between duration of symptoms and 3-month changes in BCVA was evaluated. Results: In 24 eyes, the logarithm of minimal angle of resolution BCVA before the injection and 1 and 3 months after the injection was 0.56 ± 0.25, 0.42 ± 0.26 and 0.45 ± 0.27, respectively. The CFT was 550.2 ± 116.5 μm, 270.3 ± 101.5 μm, and 356.6 ± 173.7 μm, respectively. When compared with the baseline values, the BCVA at 3 months was significantly improved (p = 0.018) and the CFT was significantly decreased (p < 0.001). There was a significant negative association between the duration of symptoms and 3-month changes in BCVA (p = 0.032, r = -0.375). Elevated intraocular pressure was observed in 3 eyes (12.5%). Conclusions: Intravitreal dexamethasone implant was found effective in treating macular edema secondary to BRVO. However, rebound macular edema and deterioration in visual acuity after 1 month suggest further studies with longer follow-ups are necessary. J Korean Ophthalmol Soc 2015;56(1):39-46

나이관련황반변성에 대한 항혈관내피성장인자 14회 유리체내주사: 완료시기와 임상결과

한재욱(Jae Wook Han),김종우(Jong Woo Kim),김철구(Chul Gu Kim),이동원(Dong Won Lee),한정일(Jung Il Han),유영주(Young Ju Lew),김재휘(Jae Hui Kim) 대한안과학회 2017 대한안과학회지 Vol.58 No.9

Purpose: To evaluate the clinical course of patients who had completed 14 ranibizumab or aflibercept monocular treatments. Methods: Retrospective medical record analysis was performed to 24 patients who were diagnosed with monocular neovascular age-related macular degeneration and had completed 14 ranibizumab or aflibercept monocular injections, allowed by the Korean National Health Care system. Time to completion was measured along with the percentage and timing of medication switch. Best-corrected visual acuity (BCVA) was measured at the time of diagnosis, after 3-loading injections, and the time of completion. Additionally, we searched for any other factors that had influenced the time to completion. Results: The average time to completion of 14 injections was 32.3 ± 6.2 months (21–48 months). The switching was performed in 17 eyes (70.8%), and it was done after 9.4 ± 2.1 injections (4–14 injections) with prior medication. After 14 injections, the BCVA improved in 6 eyes (25.0%), unchanged in 8 eyes (33.3%), and worsened in 10 eyes (41.7%). Complete resolution of intraretinal fluid and subretinal fluid after 3 loading injections were observed in 20 eyes, and it was significantly related to time to the first recurrence and time to the completion of 14 injections (p = 0.007, r = 0.583). Conclusions: The average time to completion of 14 injections was 32.3 months, and switching of medication was performed in 70.8%. Longer time to the first recurrence was related to longer completion time. This study will provide useful facts when informing the patients their future treatment plans under the Korean Health Care system. J Korean Ophthalmol Soc 2017;58(9):1042-1049